Natural killer cell biology illuminated by primary immunodeficiency syndromes in humans

Clinical Immunology

Volumn 177, Issue , 2017, Pages 29-42

  Voss, Matthias ^a   Bryceson, Yenan T ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Natural killer cell biology; Natural killer cell deficiency; Natural killer cells; Primary immunodeficiency

Indexed keywords

ARTICLE; BIOGENESIS; CELL ACTIVATION; CELL COUNT; CELL FUNCTION; CELL GRANULE; CELL MATURATION; CELL MIGRATION; CELL SURVIVAL; CYTOTOXICITY; DEVELOPMENT; EXOCYTOSIS; GENE MUTATION; GENETIC DISORDER; GENETIC VARIATION; HEMOPHAGOCYTIC SYNDROME; HETEROZYGOTE; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYNAPSE; LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPSE; ANIMAL; GENETICS; IMMUNOLOGY;

ANIMALS; GENETIC VARIATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; KILLER CELLS, NATURAL;

EID: 84949655225     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.11.004     Document Type: Article

References (191)

1. Vivier, E., Tomasello, E., Baratin, M., Walzer, T., Ugolini, S., Functions of natural killer cells. Nat. Immunol. 9 (2008), 503–510, 10.1038/ni1582.
2. Moffett, A., Colucci, F., Uterine NK cells: active regulators at the maternal-fetal interface. J. Clin. Invest. 124 (2014), 1872–1879, 10.1172/JCI68107.
3. Schlums, H., Cichocki, F., Tesi, B., Theorell, J., Béziat, V., Holmes, T.D., et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42 (2015), 443–456, 10.1016/j.immuni.2015.02.008.
4. Lee, J., Zhang, T., Hwang, I., Kim, A., Nitschke, L., Kim, M., et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 42 (2015), 431–442, 10.1016/j.immuni.2015.02.013.
5. Paust, S., von Andrian, U.H., Natural killer cell memory. Nat. Immunol. 12 (2011), 500–508, 10.1038/ni.2032.
6. Reeves, R.K., Li, H., Jost, S., Blass, E., Li, H., Schafer, J.L., et al. Antigen-specific NK cell memory in rhesus macaques. Nat. Immunol. 16 (2015), 927–932, 10.1038/ni.3227.
7. Orange, J.S., Natural killer cell deficiency. J. Allergy Clin. Immunol. 132 (2013), 515–525, 10.1016/j.jaci.2013.07.020.
8. Lanier, L.L., Evolutionary struggles between NK cells and viruses. Nat. Rev. Immunol. 8 (2008), 259–268, 10.1038/nri2276.
9. Parham, P., Moffett, A., Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat. Rev. Immunol. 13 (2013), 133–144, 10.1038/nri3370.
10. Jost, S., Altfeld, M., Control of human viral infections by natural killer cells. Annu. Rev. Immunol. 31 (2013), 163–194, 10.1146/annurev-immunol-032712-100001.
11. Waldhauer, I., Steinle, A., NK cells and cancer immunosurveillance. Oncogene 27 (2008), 5932–5943, 10.1038/onc.2008.267.
12. Shaw, R.K., Issekutz, A.C., Fraser, R., Schmit, P., Morash, B., Monaco-Shawver, L., et al. Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. Blood 119 (2012), 4009–4012, 10.1182/blood-2011-10-385377.
13. Imai, K., Matsuyama, S., Miyake, S., Suga, K., Nakachi, K., Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356 (2000), 1795–1799, 10.1016/S0140-6736(00)03231-1.
14. Wood, S.M., Ljunggren, H.-G., Bryceson, Y.T., Insights into NK cell biology from human genetics and disease associations. Cell. Mol. Life Sci. 68 (2011), 3479–3493, 10.1007/s00018-011-0799-y.
15. Biron, C.A., Byron, K.S., Sullivan, J.L., Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320 (1989), 1731–1735, 10.1056/NEJM198906293202605.
16. Yu, J., Freud, A.G., Caligiuri, M.A., Location and cellular stages of natural killer cell development. Trends Immunol. 34 (2013), 573–582, 10.1016/j.it.2013.07.005.
17. Cichocki, F., Sitnicka, E., Bryceson, Y.T., NK cell development and function — plasticity and redundancy unleashed. Semin. Immunol. 26 (2014), 114–126, 10.1016/j.smim.2014.02.003.
18. Caligiuri, M.A., Human natural killer cells. Blood 112 (2008), 461–469, 10.1182/blood-2007-09-077438.
19. Jouanguy, E., Gineau, L., Cottineau, J., Béziat, V., Vivier, E., Casanova, J.L., Inborn errors of the development of human natural killer cells. Curr. Opin. Allergy Clin. Immunol. 13 (2013), 589–595, 10.1097/ACI.0000000000000011.
20. Mace, E.M., Hsu, A.P., Monaco-Shawver, L., Makedonas, G., Rosen, J.B., Dropulic, L., et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood 121 (2013), 2669–2677, 10.1182/blood-2012-09-453969.
21. Spinner, M.A., Sanchez, L.A., Hsu, A.P., Shaw, P.A., Zerbe, C.S., Calvo, K.R., et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 123 (2014), 809–821, 10.1182/blood-2013-07-515528.
22. Hsu, A.P., Sampaio, E.P., Khan, J., Calvo, K.R., Lemieux, J.E., Patel, S.Y., et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 118 (2011), 2653–2655, 10.1182/blood-2011-05-356352.
23. Hahn, C.N., Chong, C.-E., Carmichael, C.L., Wilkins, E.J., Brautigan, P.J., Li, X.-C., et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat. Genet. 43 (2011), 1012–1017, 10.1038/ng.913.
24. Ostergaard, P., Simpson, M.A., Connell, F.C., Steward, C.G., Brice, G., Woollard, W.J., et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat. Genet. 43 (2011), 929–931, 10.1038/ng.923.
25. Bigley, V., Haniffa, M., Doulatov, S., Wang, X.-N., Dickinson, R., McGovern, N., et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J. Exp. Med. 208 (2011), 227–234, 10.1084/jem.20101459.
26. Dickinson, R.E., Griffin, H., Bigley, V., Reynard, L.N., Hussain, R., Haniffa, M., et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 118 (2011), 2656–2658, 10.1182/blood-2011-06-360313.
27. Dickinson, R.E., Milne, P., Jardine, L., Zandi, S., Swierczek, S.I., McGovern, N., et al. The evolution of cellular deficiency in GATA2 mutation. Blood 123 (2014), 863–874, 10.1182/blood-2013-07-517151.
28. Tsuzuki, S., Enver, T., Interactions of GATA-2 with the promyelocytic leukemia zinc finger (PLZF) protein, its homologue FAZF, and the t(11;17)-generated PLZF-retinoic acid receptor alpha oncoprotein. Blood 99 (2002), 3404–3410.
29. Eidson, M., Wahlstrom, J., Beaulieu, A.M., Zaidi, B., Carsons, S.E., Crow, P.K., et al. Altered development of NKT cells, γδ T cells, CD8 T cells and NK cells in a PLZF deficient patient. PLoS ONE, 6, 2011, e24441, 10.1371/journal.pone.0024441.
30. O'Riordan, S.M.P., Lynch, S.A., Hindmarsh, P.C., Chan, L.F., Clark, A.J.L., Costigan, C., A novel variant of familial glucocorticoid deficiency prevalent among the Irish traveler population. J. Clin. Endocrinol. Metab. 93 (2008), 2896–2899, 10.1210/jc.2008-0034.
31. Eidenschenk, C., Dunne, J., Jouanguy, E., Fourlinnie, C., Gineau, L., Bacq, D., et al. A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am. J. Hum. Genet. 78 (2006), 721–727, 10.1086/503269.
32. Gineau, L., Cognet, C., Kara, N., Lach, F.P., Dunne, J., Veturi, U., et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J. Clin. Invest. 122 (2012), 821–832, 10.1172/JCI61014.
33. Hughes, C.R., Guasti, L., Meimaridou, E., Chuang, C.-H., Schimenti, J.C., King, P.J., et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J. Clin. Invest. 122 (2012), 814–820, 10.1172/JCI60224.
34. Bochman, M.L., Schwacha, A., The Mcm complex: unwinding the mechanism of a replicative helicase. Microbiol. Mol. Biol. Rev. 73 (2009), 652–683, 10.1128/MMBR.00019-09.
35. Ilves, I., Petojevic, T., Pesavento, J.J., Botchan, M.R., Activation of the MCM2-7 helicase by association with Cdc45 and GINS proteins. Mol. Cell 37 (2010), 247–258, 10.1016/j.molcel.2009.12.030.
36. Orr, M.T., Murphy, W.J., Lanier, L.L., “Unlicensed” natural killer cells dominate the response to cytomegalovirus infection. Nat. Immunol. 11 (2010), 321–327, 10.1038/ni.1849.
37. Al-Herz, W., Bousfiha, A., Casanova, J.L., Chatila, T., Conley, M.E., Cunningham-Rundles, C., et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front. Immunol., 5, 2014, 162, 10.3389/fimmu.2014.00162.
38. Kamili, Q.U.A., Seeborg, F.O., Saxena, K., Nicholas, S.K., Banerjee, P.P., Angelo, L.S., et al. Severe cutaneous human papillomavirus infection associated with natural killer cell deficiency following stem cell transplantation for severe combined immunodeficiency. J. Allergy Clin. Immunol. 134 (2014), 1451–1453, 10.1016/j.jaci.2014.07.009.
39. Kovanen, P.E., Leonard, W.J., Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 202 (2004), 67–83, 10.1111/j.0105-2896.2004.00203.x.
40. Noguchi, M., Yi, H., Rosenblatt, H.M., Filipovich, A.H., Adelstein, S., Modi, W.S., et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73 (1993), 147–157.
41. Buckley, R.H., Schiff, R.I., Schiff, S.E., Markert, M.L., Williams, L.W., Harville, T.O., et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J. Pediatr. 130 (1997), 378–387.
42. Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., De Coene, C., Selz, F., Le Deist, F., et al. Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency X1 bone marrow cells. Blood 88 (1996), 3901–3909.
43. Gilmour, K.C., Fujii, H., Cranston, T., Davies, E.G., Kinnon, C., Gaspar, H.B., Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood 98 (2001), 877–879.
44. Lebrec, H., Horner, M.J., Gorski, K.S., Tsuji, W., Xia, D., Pan, W.-J., et al. Homeostasis of human NK cells is not IL-15 dependent. J. Immunol. 191 (2013), 5551–5558, 10.4049/jimmunol.1301000.
45. Kotlarz, D., Ziętara, N., Uzel, G., Weidemann, T., Braun, C.J., Diestelhorst, J., et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J. Exp. Med. 210 (2013), 433–443, 10.1084/jem.20111229.
46. Russell, S.M., Tayebi, N., Nakajima, H., Riedy, M.C., Roberts, J.L., Aman, M.J., et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270 (1995), 797–800.
47. Macchi, P., Villa, A., Giliani, S., Sacco, M.G., Frattini, A., Porta, F., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377 (1995), 65–68, 10.1038/377065a0.
48. Nadeau, K., Hwa, V., Rosenfeld, R.G., STAT5b deficiency: an unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease. J. Pediatr. 158 (2011), 701–708, 10.1016/j.jpeds.2010.12.042.
49. Bezrodnik, L., Di Giovanni, D., Caldirola, M.S., Azcoiti, M.E., Torgerson, T., Gaillard, M.I., Long-term follow-up of STAT5B deficiency in three Argentinian patients: clinical and immunological features. J. Clin. Immunol. 35 (2015), 264–272, 10.1007/s10875-015-0145-5.
50. Rajala, H.L.M., Eldfors, S., Kuusanmäki, H., van Adrichem, A.J., Olson, T., Lagström, S., et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 121 (2013), 4541–4550, 10.1182/blood-2012-12-474577.
51. Jerez, A., Clemente, M.J., Makishima, H., Koskela, H., Leblanc, F., Peng Ng, K., et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120 (2012), 3048–3057, 10.1182/blood-2012-06-435297.
52. Zhu, S., Phatarpekar, P.V., Denman, C.J., Senyukov, V.V., Somanchi, S.S., Nguyen-Jackson, H.T., et al. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood 124 (2014), 403–411, 10.1182/blood-2013-05-499707.
53. Korthof, E.T., Svahn, J., Peffault de Latour, R., Terranova, P., Moins-Teisserenc, H., Socié, G., et al. Immunological profile of Fanconi anemia: a multicentric retrospective analysis of 61 patients. Am. J. Hematol. 88 (2013), 472–476, 10.1002/ajh.23435.
54. Bonthron, D.T., Markham, A.F., Ginsburg, D., Orkin, S.H., Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency. J. Clin. Invest. 76 (1985), 894–897, 10.1172/JCI112050.
55. Keller, M.D., Ganesh, J., Heltzer, M., Paessler, M., Bergqvist, A.G.C., Baluarte, H.J., et al. Severe combined immunodeficiency resulting from mutations in MTHFD1. Pediatrics 131 (2013), e629–e634, 10.1542/peds.2012-0899.
56. El-Sherbiny, Y.M., Doody, G.M., Kelly, R.J., Hill, A., Hillmen, P., Cook, G.P., Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: a deficiency of NK cells, but not an NK cell deficiency. Blood 125 (2015), 1351–1352, 10.1182/blood-2014-07-591255.
57. Guia, S., Cognet, C., de Beaucoudrey, L., Tessmer, M.S., Jouanguy, E., Berger, C., et al. A role for interleukin-12/23 in the maturation of human natural killer and CD56 + T cells in vivo. Blood 111 (2008), 5008–5016, 10.1182/blood-2007-11-122259.
58. Marquardt, N., Béziat, V., Nyström, S., Hengst, J., Ivarsson, M.A., Kekäläinen, E., et al. Cutting edge: identification and characterization of human intrahepatic CD49a + NK cells. J. Immunol. 194 (2015), 2467–2471, 10.4049/jimmunol.1402756.
59. Wu, C., Li, B., Lu, R., Koelle, S.J., Yang, Y., Jares, A., et al. Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage origin for natural killer cells. Cell Stem Cell 14 (2014), 486–499, 10.1016/j.stem.2014.01.020.
60. Bryceson, Y.T., Chiang, S.C.C., Darmanin, S., Fauriat, C., Schlums, H., Theorell, J., et al. Molecular mechanisms of natural killer cell activation. J Innate Immun. 3 (2011), 216–226, 10.1159/000325265.
61. Long, E.O., Kim, H.S., Liu, D., Peterson, M.E., Rajagopalan, S., Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31 (2013), 227–258, 10.1146/annurev-immunol-020711-075005.
62. Krzewski, K., Coligan, J.E., Human NK cell lytic granules and regulation of their exocytosis. Front. Immunol., 3, 2012, 335, 10.3389/fimmu.2012.00335.
63. Mace, E.M., Dongre, P., Hsu, H.-T., Sinha, P., James, A.M., Mann, S.S., et al. Cell biological steps and checkpoints in accessing NK cell cytotoxicity. Immunol. Cell Biol. 92 (2014), 245–255, 10.1038/icb.2013.96.
64. Bryceson, Y.T., Ljunggren, H.-G., Long, E.O., Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 114 (2009), 2657–2666, 10.1182/blood-2009-01-201632.
65. Kishimoto, T.K., Hollander, N., Roberts, T.M., Anderson, D.C., Springer, T.A., Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency. Cell 50 (1987), 193–202.
66. Kohl, S., Springer, T.A., Schmalstieg, F.C., Loo, L.S., Anderson, D.C., Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency. J. Immunol. 133 (1984), 2972–2978.
67. Kohl, S., Loo, L.S., Schmalstieg, F.S., Anderson, D.C., The genetic deficiency of leukocyte surface glycoprotein Mac-1, LFA-1, p150,95 in humans is associated with defective antibody-dependent cellular cytotoxicity in vitro and defective protection against herpes simplex virus infection in vivo. J. Immunol. 137 (1986), 1688–1694.
68. Lau, Y.L., Low, L.C., Jones, B.M., Lawton, J.W., Defective neutrophil and lymphocyte function in leucocyte adhesion deficiency. Clin. Exp. Immunol. 85 (1991), 202–208.
69. James, A.M., Hsu, H.-T., Dongre, P., Uzel, G., Mace, E.M., Banerjee, P.P., et al. Rapid activation receptor- or IL-2-induced lytic granule convergence in human natural killer cells requires Src, but not downstream signaling. Blood 121 (2013), 2627–2637, 10.1182/blood-2012-06-437012.
70. Bryceson, Y.T., March, M.E., Barber, D.F., Ljunggren, H.-G., Long, E.O., Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp. Med. 202 (2005), 1001–1012, 10.1084/jem.20051143.
71. Castriconi, R., Dondero, A., Cantoni, C., Della Chiesa, M., Prato, C., Nanni, M., et al. Functional characterization of natural killer cells in type I leukocyte adhesion deficiency. Blood 109 (2007), 4873–4881, 10.1182/blood-2006-08-038760.
72. Gruda, R., Brown, A.C.N., Grabovsky, V., Mizrahi, S., Gur, C., Feigelson, S.W., et al. Loss of kindlin-3 alters the threshold for NK cell activation in human leukocyte adhesion deficiency-III. Blood 120 (2012), 3915–3924, 10.1182/blood-2012-02-410795.
73. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002), 754–758.
74. Jawahar, S., Moody, C., Chan, M., Finberg, R., Geha, R., Chatila, T., Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin. Exp. Immunol. 103 (1996), 408–413.
75. de Vries, E., Koene, H.R., Vossen, J.M., Gratama, J.W., von dem Borne, A.E., Waaijer, J.L., et al. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 88 (1996), 3022–3027.
76. Grier, J.T., Forbes, L.R., Monaco-Shawver, L., Oshinsky, J., Atkinson, T.P., Moody, C., et al. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J. Clin. Invest. 122 (2012), 3769–3780, 10.1172/JCI64837.
77. Miyashita, R., Tsuchiya, N., Hikami, K., Kuroki, K., Fukazawa, T., Bijl, M., et al. Molecular genetic analyses of human NKG2C (KLRC2) gene deletion. Int. Immunol. 16 (2004), 163–168, 10.1093/intimm/dxh013.
78. Lopez-Verges, S., Milush, J.M., Schwartz, B.S., Pando, M.J., Jarjoura, J., York, V.A., et al. Expansion of a unique CD57 ⁺ NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 14725–14732, 10.1073/pnas.1110900108.
79. Goodier, M.R., White, M.J., Darboe, A., Nielsen, C.M., Goncalves, A., Bottomley, C., et al. Rapid NK cell differentiation in a population with near-universal human cytomegalovirus infection is attenuated by NKG2C deletions. Blood 124 (2014), 2213–2222, 10.1182/blood-2014-05-576124.
80. Furukawa, H., Yabe, T., Watanabe, K., Miyamoto, R., Miki, A., Akaza, T., et al. Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). Hum. Immunol. 60 (1999), 32–40.
81. de la Salle, H., Hanau, D., Fricker, D., Urlacher, A., Kelly, A., Salamero, J., et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 265 (1994), 237–241.
82. Zimmer, J., Donato, L., Hanau, D., Cazenave, J.P., Tongio, M.M., Moretta, A., et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J. Exp. Med. 187 (1998), 117–122.
83. Markel, G., Mussaffi, H., Ling, K.-L., Salio, M., Gadola, S., Steuer, G., et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 103 (2004), 1770–1778, 10.1182/blood-2003-06-2114.
84. Ardeniz, Ö., Unger, S., Onay, H., Ammann, S., Keck, C., Cianga, C., et al. β2-microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system. J. Allergy Clin. Immunol. 136 (2015), 392–401, 10.1016/j.jaci.2014.12.1937.
85. Zheng, P., Noroski, L.M., Hanson, I.C., Chen, Y., Lee, M.E., Huang, Y., et al. Molecular mechanisms of functional natural killer deficiency in patients with partial DiGeorge syndrome. J. Allergy Clin. Immunol. 135 (2015), 1293–1302, 10.1016/j.jaci.2015.01.011.
86. Segovis, C.M., Schoon, R.A., Dick, C.J., Nacusi, L.P., Leibson, P.J., Billadeau, D.D., PI3K links NKG2D signaling to a CrkL pathway involved in natural killer cell adhesion, polarity, and granule secretion. J. Immunol. 182 (2009), 6933–6942, 10.4049/jimmunol.0803840.
87. Liu, D., Peterson, M.E., Long, E.O., The adaptor protein Crk controls activation and inhibition of natural killer cells. Immunity 36 (2012), 600–611, 10.1016/j.immuni.2012.03.007.
88. Coffey, A.J., Brooksbank, R.A., Brandau, O., Oohashi, T., Howell, G.R., Bye, J.M., et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat. Genet. 20 (1998), 129–135, 10.1038/2424.
89. Ma, C.S., Nichols, K.E., Tangye, S.G., Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu. Rev. Immunol. 25 (2007), 337–379, 10.1146/annurev.immunol.25.022106.141651.
90. Bassiri, H., Janice Yeo, W.C., Rothman, J., Koretzky, G.A., Nichols, K.E., X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses. Immunol. Res. 42 (2008), 145–159, 10.1007/s12026-008-8048-7.
91. Tangye, S.G., Phillips, J.H., Lanier, L.L., Nichols, K.E., Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J. Immunol. 165 (2000), 2932–2936.
92. Benoit, L., Wang, X., Pabst, H.F., Dutz, J., Tan, R., Defective NK cell activation in X-linked lymphoproliferative disease. J. Immunol. 165 (2000), 3549–3553.
93. Nakajima, H., Cella, M., Bouchon, A., Grierson, H.L., Lewis, J., Duckett, C.S., et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur. J. Immunol. 30 (2000), 3309–3318.
94. Dupré, L., Andolfi, G., Tangye, S.G., Clementi, R., Locatelli, F., Arico, M., et al. SAP controls the cytolytic activity of CD8 + T cells against EBV-infected cells. Blood 105 (2005), 4383–4389, 10.1182/blood-2004-08-3269.
95. Dong, Z., Davidson, D., Pérez-Quintero, L.A., Kurosaki, T., Swat, W., Veillette, A., The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells. Immunity 36 (2012), 974–985, 10.1016/j.immuni.2012.03.023.
96. Derry, J.M., Ochs, H.D., Francke, U., Isolation of a novel gene mutated in Wiskott–Aldrich syndrome. Cell 78 (1994), 635–644.
97. Orange, J.S., Stone, K.D., Turvey, S.E., Krzewski, K., The Wiskott–Aldrich syndrome. Cell. Mol. Life Sci. 61 (2004), 2361–2385, 10.1007/s00018-004-4086-z.
98. Orange, J.S., Ramesh, N., Remold-O'Donnell, E., Sasahara, Y., Koopman, L., Byrne, M., et al. Wiskott–Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 11351–11356, 10.1073/pnas.162376099.
99. Gismondi, A., Cifaldi, L., Mazza, C., Giliani, S., Parolini, S., Morrone, S., et al. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood 104 (2004), 436–443, 10.1182/blood-2003-07-2621.
100. Orange, J.S., Roy-Ghanta, S., Mace, E.M., Maru, S., Rak, G.D., Sanborn, K.B., et al. IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. J. Clin. Invest. 121 (2011), 1535–1548, 10.1172/JCI44862.
101. Lanzi, G., Moratto, D., Vairo, D., Masneri, S., Delmonte, O., Paganini, T., et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. J. Exp. Med. 209 (2012), 29–34, 10.1084/jem.20110896.
102. Aydin, S.E., Kilic, S.S., Aytekin, C., Kumar, A., Porras, O., Kainulainen, L., et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. J. Clin. Immunol. 35 (2015), 189–198, 10.1007/s10875-014-0126-0.
103. Jing, H., Zhang, Q., Zhang, Y., Hill, B.J., Dove, C.G., Gelfand, E.W., et al. Somatic reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease phenotype. J. Allergy Clin. Immunol. 133 (2014), 1667–1675, 10.1016/j.jaci.2014.03.025.
104. Mizesko, M.C., Banerjee, P.P., Monaco-Shawver, L., Mace, E.M., Bernal, W.E., Sawalle-Belohradsky, J., et al. Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiency. J. Allergy Clin. Immunol. 131 (2013), 840–848, 10.1016/j.jaci.2012.12.1568.
105. Ham, H., Guerrier, S., Kim, J., Schoon, R.A., Anderson, E.L., Hamann, M.J., et al. Dedicator of cytokinesis 8 interacts with talin and Wiskott–Aldrich syndrome protein to regulate NK cell cytotoxicity. J. Immunol. 190 (2013), 3661–3669, 10.4049/jimmunol.1202792.
106. Stabile, H., Carlino, C., Mazza, C., Giliani, S., Morrone, S., Notarangelo, L.D., et al. Impaired NK-cell migration in WAS/XLT patients: role of Cdc42/WASp pathway in the control of chemokine-induced beta2 integrin high-affinity state. Blood 115 (2010), 2818–2826, 10.1182/blood-2009-07-235804.
107. Zhang, Q., Dove, C.G., Hor, J.L., Murdock, H.M., Strauss-Albee, D.M., Garcia, J.A., et al. DOCK8 regulates lymphocyte shape integrity for skin antiviral immunity. J. Exp. Med. 211 (2014), 2549–2566, 10.1084/jem.20141307.
108. Vairo, D., Tassone, L., Tabellini, G., Tamassia, N., Gasperini, S., Bazzoni, F., et al. Severe impairment of IFN-γ and IFN-α responses in cells of a patient with a novel STAT1 splicing mutation. Blood 118 (2011), 1806–1817, 10.1182/blood-2011-01-330571.
109. Chun, H.J., Zheng, L., Ahmad, M., Wang, J., Speirs, C.K., Siegel, R.M., et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419 (2002), 395–399, 10.1038/nature01063.
110. Su, H., Bidère, N., Zheng, L., Cubre, A., Sakai, K., Dale, J., et al. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 307 (2005), 1465–1468, 10.1126/science.1104765.
111. Orange, J.S., Brodeur, S.R., Jain, A., Bonilla, F.A., Schneider, L.C., Kretschmer, R., et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J. Clin. Invest. 109 (2002), 1501–1509, 10.1172/JCI14858.
112. Lougaris, V., Tabellini, G., Vitali, M., Baronio, M., Patrizi, O., Tampella, G., et al. Defective natural killer-cell cytotoxic activity in NFKB2-mutated CVID-like disease. J. Allergy Clin. Immunol. 135 (2015), 1641–1643, 10.1016/j.jaci.2014.11.038.
113. Chen, K., Coonrod, E.M., Kumánovics, A., Franks, Z.F., Durtschi, J.D., Margraf, R.L., et al. Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency. Am. J. Hum. Genet. 93 (2013), 812–824, 10.1016/j.ajhg.2013.09.009.
114. Willmann, K.L., Klaver, S., Doğu, F., Santos-Valente, E., Garncarz, W., Bilic, I., et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat. Commun., 5, 2014, 5360, 10.1038/ncomms6360.
115. Ombrello, M.J., Remmers, E.F., Sun, G., Freeman, A.F., Datta, S., Torabi-Parizi, P., et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N. Engl. J. Med. 366 (2012), 330–338, 10.1056/NEJMoa1102140.
116. Maul-Pavicic, A., Chiang, S.C.C., Rensing-Ehl, A., Jessen, B., Fauriat, C., Wood, S.M., et al. ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 3324–3329, 10.1073/pnas.1013285108.
117. Chou, J., Badran, Y.R., Yee, C.S.K., Bainter, W., Ohsumi, T.K., Al-Hammadi, S., et al. A novel mutation in ORAI1 presenting with combined immunodeficiency and residual T-cell function. J. Allergy Clin. Immunol. 136 (2015), 479–482.e1, 10.1016/j.jaci.2015.03.050.
118. Voskoboinik, I., Whisstock, J.C., Trapani, J.A., Perforin and granzymes: function, dysfunction and human pathology. Nat. Rev. Immunol. 15 (2015), 388–400, 10.1038/nri3839.
119. de Saint Basile, G., Ménasché, G., Fischer, A., Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat. Rev. Immunol. 10 (2010), 568–579, 10.1038/nri2803.
120. Meeths, M., Chiang, S.C.C., Löfstedt, A., Müller, M.-L., Tesi, B., Henter, J.-I., et al. Pathophysiology and spectrum of diseases caused by defects in lymphocyte cytotoxicity. Exp. Cell Res. 325 (2014), 10–17, 10.1016/j.yexcr.2014.03.014.
121. Löfsted, A., Chiang, S.S.C., Onelöv, E., Bryceson, Y.T., Meeths, M., Henter, J.I., Cancer risk in relatives of patients with primary defects in lymphocyte cytotoxicity: a retrospective cohort study. Lancet Hematology, 2015 in press.
122. Stepp, S.E., Dufourcq-Lagelouse, R., Le Deist, F., Bhawan, S., Certain, S., Mathew, P.A., et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286 (1999), 1957–1959.
123. Sieni, E., Cetica, V., Santoro, A., Beutel, K., Mastrodicasa, E., Meeths, M., et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. J. Med. Genet. 48 (2011), 343–352, 10.1136/jmg.2010.085456.
124. Sepulveda, F.E., Debeurme, F., Ménasché, G., Kurowska, M., Côte, M., Pachlopnik Schmid, J., et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11. Blood 121 (2013), 595–603, 10.1182/blood-2012-07-440339.
125. Jordan, M.B., Hildeman, D., Kappler, J., Marrack, P., An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8 + T cells and interferon gamma are essential for the disorder. Blood 104 (2004), 735–743, 10.1182/blood-2003-10-3413.
126. Voskoboinik, I., Dunstone, M.A., Baran, K., Whisstock, J.C., Trapani, J.A., Perforin: structure, function, and role in human immunopathology. Immunol. Rev. 235 (2010), 35–54, 10.1111/j.0105-2896.2010.00896.x.
127. Pham, C.T., Ley, T.J., Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 8627–8632.
128. Meade, J.L., de Wynter, E.A., Brett, P., Sharif, S.M., Woods, C.G., Markham, A.F., et al. A family with Papillon–Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activity. Blood 107 (2006), 3665–3668, 10.1182/blood-2005-03-1140.
129. Jenkins, M.R., Rudd-Schmidt, J.A., Lopez, J.A., Ramsbottom, K.M., Mannering, S.I., Andrews, D.M., et al. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J. Exp. Med. 212 (2015), 307–317, 10.1084/jem.20140964.
130. Kaplan, J., De Domenico, I., Ward, D.M., Chediak–Higashi syndrome. Curr. Opin. Hematol. 15 (2008), 22–29.
131. Roder, J.C., Haliotis, T., Klein, M., Korec, S., Jett, J.R., Ortaldo, J., et al. A new immunodeficiency disorder in humans involving NK cells. Nature 284 (1980), 553–555.
132. Baetz, K., Isaaz, S., Griffiths, G.M., Loss of cytotoxic T lymphocyte function in Chediak–Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J. Immunol. 154 (1995), 6122–6131.
133. Stinchcombe, J.C., Page, L.J., Griffiths, G.M., Secretory lysosome biogenesis in cytotoxic T lymphocytes from normal and Chediak–Higashi syndrome patients. Traffic 1 (2000), 435–444.
134. Nagle, D.L., Karim, M.A., Woolf, E.A., Holmgren, L., Bork, P., Misumi, D.J., et al. Identification and mutation analysis of the complete gene for Chediak–Higashi syndrome. Nat. Genet. 14 (1996), 307–311, 10.1038/ng1196-307.
135. Jessen, B., Maul-Pavicic, A., Ufheil, H., Vraetz, T., Enders, A., Lehmberg, K., et al. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak–Higashi syndrome. Blood 118 (2011), 4620–4629, 10.1182/blood-2011-05-356113.
136. Cullinane, A.R., Schäffer, A.A., Huizing, M., The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease. Traffic 14 (2013), 749–766, 10.1111/tra.12069.
137. Perou, C.M., Leslie, J.D., Green, W., Li, L., Ward, D.M., Kaplan, J., The beige/Chediak–Higashi syndrome gene encodes a widely expressed cytosolic protein. J. Biol. Chem. 272 (1997), 29790–29794.
138. Durchfort, N., Verhoef, S., Vaughn, M.B., Shrestha, R., Adam, D., Kaplan, J., et al. The enlarged lysosomes in beige j cells result from decreased lysosome fission and not increased lysosome fusion. Traffic 13 (2012), 108–119, 10.1111/j.1600-0854.2011.01300.x.
139. Sepulveda, F.E., Burgess, A., Heiligenstein, X., Goudin, N., Ménager, M.M., Romao, M., et al. LYST controls the biogenesis of the endosomal compartment required for secretory lysosome function. Traffic 16 (2015), 191–203, 10.1111/tra.12244.
140. Shotelersuk, V., Dell'Angelica, E.C., Hartnell, L., Bonifacino, J.S., Gahl, W.A., A new variant of Hermansky–Pudlak syndrome due to mutations in a gene responsible for vesicle formation. Am. J. Med. 108 (2000), 423–427.
141. Clark, R.H., Stinchcombe, J.C., Day, A., Blott, E., Booth, S., Bossi, G., et al. Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat. Immunol. 4 (2003), 1111–1120, 10.1038/ni1000.
142. Badolato, R., Prandini, A., Caracciolo, S., Colombo, F., Tabellini, G., Giacomelli, M., et al. Exome sequencing reveals a pallidin mutation in a Hermansky–Pudlak-like primary immunodeficiency syndrome. Blood 119 (2012), 3185–3187, 10.1182/blood-2012-01-404350.
143. Setty, S.R.G., Tenza, D., Truschel, S.T., Chou, E., Sviderskaya, E.V., Theos, A.C., et al. BLOC-1 is required for cargo-specific sorting from vacuolar early endosomes toward lysosome-related organelles. Mol. Biol. Cell 18 (2007), 768–780, 10.1091/mbc.E06-12-1066.
144. Liu, D., Bryceson, Y.T., Meckel, T., Vasiliver-Shamis, G., Dustin, M.L., Long, E.O., Integrin-dependent organization and bidirectional vesicular traffic at cytotoxic immune synapses. Immunity 31 (2009), 99–109, 10.1016/j.immuni.2009.05.009.
145. Zhang, M., March, M.E., Lane, W.S., Long, E.O., A signaling network stimulated by β2 integrin promotes the polarization of lytic granules in cytotoxic cells. Sci. Signal., 7, 2014, ra96, 10.1126/scisignal.2005629.
146. Mentlik, A.N., Sanborn, K.B., Holzbaur, E.L., Orange, J.S., Rapid lytic granule convergence to the MTOC in natural killer cells is dependent on dynein but not cytolytic commitment. Mol. Biol. Cell 21 (2010), 2241–2256, 10.1091/mbc.E09-11-0930.
147. Ménasché, G., Pastural, E., Feldmann, J., Certain, S., Ersoy, F., Dupuis, S., et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat. Genet. 25 (2000), 173–176, 10.1038/76024.
148. Pachlopnik Schmid, J., Ho, C.-H., Diana, J., Pivert, G., Lehuen, A., Geissmann, F., et al. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH). Eur. J. Immunol. 38 (2008), 3219–3225, 10.1002/eji.200838488.
149. Pastural, E., Barrat, F.J., Dufourcq-Lagelouse, R., Certain, S., Sanal, O., Jabado, N., et al. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat. Genet. 16 (1997), 289–292, 10.1038/ng0797-289.
150. Ménasché, G., Ho, C.-H., Sanal, Ö., Feldmann, J., Tezcan, I., Ersoy, F., et al. Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). J. Clin. Invest. 112 (2003), 450–456, 10.1172/JCI18264.
151. Ménasché, G., Ménager, M.M., Lefebvre, J.M., Deutsch, E., Athman, R., Lambert, N., et al. A newly identified isoform of Slp2a associates with Rab27a in cytotoxic T cells and participates to cytotoxic granule secretion. Blood 112 (2008), 5052–5062, 10.1182/blood-2008-02-141069.
152. Holt, O., Kanno, E., Bossi, G., Booth, S., Daniele, T., Santoro, A., et al. Slp1 and Slp2-a localize to the plasma membrane of CTL and contribute to secretion from the immunological synapse. Traffic 9 (2008), 446–457, 10.1111/j.1600-0854.2008.00714.x.
153. Kurowska, M., Goudin, N., Nehme, N.T., Court, M., Garin, J., Fischer, A., et al. Terminal transport of lytic granules to the immune synapse is mediated by the kinesin-1/Slp3/Rab27a complex. Blood 119 (2012), 3879–3889, 10.1182/blood-2011-09-382556.
154. Sanborn, K.B., Rak, G.D., Maru, S.Y., Demers, K., Difeo, A., Martignetti, J.A., et al. Myosin IIA associates with NK cell lytic granules to enable their interaction with F-actin and function at the immunological synapse. J. Immunol. 182 (2009), 6969–6984, 10.4049/jimmunol.0804337.
155. Sanborn, K.B., Mace, E.M., Rak, G.D., Difeo, A., Martignetti, J.A., Pecci, A., et al. Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity. Blood 118 (2011), 5862–5871, 10.1182/blood-2011-03-344846.
156. Seri, M., Pecci, A., Di Bari, F., Cusano, R., Savino, M., Panza, E., et al. MYH9-related disease: May–Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 82 (2003), 203–215, 10.1097/01.md.0000076006.64510.5c.
157. Feldmann, J., Callebaut, I., Raposo, G., Certain, S., Bacq, D., Dumont, C., et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115 (2003), 461–473.
158. Koch, H., Hofmann, K., Brose, N., Definition of Munc13-homology-domains and characterization of a novel ubiquitously expressed Munc13 isoform. Biochem. J. 349 (2000), 247–253.
159. Ménager, M.M., Ménasché, G., Romao, M., Knapnougel, P., Ho, C.-H., Garfa, M., et al. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat. Immunol. 8 (2007), 257–267, 10.1038/ni1431.
160. Wood, S.M., Meeths, M., Chiang, S.C.C., Bechensteen, A.G., Boelens, J.J., Heilmann, C., et al. Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood 114 (2009), 4117–4127, 10.1182/blood-2009-06-225359.
161. Elstak, E.D., Neeft, M., Nehme, N.T., Voortman, J., Cheung, M., Goodarzifard, M., et al. The munc13-4-rab27 complex is specifically required for tethering secretory lysosomes at the plasma membrane. Blood 118 (2011), 1570–1578, 10.1182/blood-2011-02-339523.
162. Cetica, V., Hackmann, Y., Grieve, S., Sieni, E., Ciambotti, B., Coniglio, M.L., et al. Patients with Griscelli syndrome and normal pigmentation identify RAB27A mutations that selectively disrupt MUNC13-4 binding. J. Allergy Clin. Immunol. 135 (2015), 1310–1318, 10.1016/j.jaci.2014.08.039.
163. Meeths, M., Chiang, S.C.C., Wood, S.M., Entesarian, M., Schlums, H., Bang, B., et al. Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood 118 (2011), 5783–5793, 10.1182/blood-2011-07-369090.
164. Entesarian, M., Chiang, S.C.C., Schlums, H., Meeths, M., Chan, M.-Y., Mya, S.-N., et al. Novel deep intronic and missense UNC13D mutations in familial haemophagocytic lymphohistiocytosis type 3. Br. J. Haematol. 162 (2013), 415–418, 10.1111/bjh.12371.
165. Seo, J.Y., Song, J.-S., Lee, K.-O., Won, H.-H., Kim, J.-W., Kim, S.-H., et al. Founder effects in two predominant intronic mutations of UNC13D, c.118-308C > T and c.754-1G > C underlie the unusual predominance of type 3 familial hemophagocytic lymphohistiocytosis (FHL3) in Korea. Ann. Hematol. 92 (2013), 357–364, 10.1007/s00277-012-1628-6.
166. Qian, Y., Johnson, J.A., Connor, J.A., Valencia, C.A., Barasa, N., Schubert, J., et al. The 253-kb inversion and deep intronic mutations in UNC13D are present in North American patients with familial hemophagocytic lymphohistiocytosis 3. Pediatr. Blood Cancer 61 (2014), 1034–1040, 10.1002/pbc.24955.
167. Cichocki, F., Schlums, H., Li, H., Stache, V., Holmes, T., Lenvik, T.R., et al. Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency. J. Exp. Med. 211 (2014), 1079–1091, 10.1084/jem.20131131.
168. Südhof, T.C., The presynaptic active zone. Neuron 75 (2012), 11–25, 10.1016/j.neuron.2012.06.012.
169. zur Stadt, U., Schmidt, S., Kasper, B., Beutel, K., Diler, A.S., Henter, J.-I., et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum. Mol. Genet. 14 (2005), 827–834, 10.1093/hmg/ddi076.
170. Côte, M., Ménager, M.M., Burgess, A., Mahlaoui, N., Picard, C., Schaffner, C., et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J. Clin. Invest. 119 (2009), 3765–3773, 10.1172/JCI40732.
171. zur Stadt, U., Rohr, J., Seifert, W., Koch, F., Grieve, S., Pagel, J., et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am. J. Hum. Genet. 85 (2009), 482–492, 10.1016/j.ajhg.2009.09.005.
172. Bryceson, Y.T., Rudd, E., Zheng, C., Edner, J., Ma, D., Wood, S.M., et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 110 (2007), 1906–1915, 10.1182/blood-2007-02-074468.
173. Hackmann, Y., Graham, S.C., Ehl, S., Höning, S., Lehmberg, K., Arico, M., et al. Syntaxin binding mechanism and disease-causing mutations in Munc18-2. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E4482–E4491, 10.1073/pnas.1313474110.
174. Valdez, A.C., Cabaniols, J.P., Brown, M.J., Roche, P.A., Syntaxin 11 is associated with SNAP-23 on late endosomes and the trans-Golgi network. J. Cell Sci. 112:Pt 6 (1999), 845–854.
175. Marshall, M.R., Pattu, V., Halimani, M., Maier-Peuschel, M., Müller, M.-L., Becherer, U., et al. VAMP8-dependent fusion of recycling endosomes with the plasma membrane facilitates T lymphocyte cytotoxicity. J. Cell Biol. 210 (2015), 135–151, 10.1083/jcb.201411093.
176. Müller, M.-L., Chiang, S.C.C., Meeths, M., Tesi, B., Entesarian, M., Nilsson, D., et al. An N-terminal missense mutation in STX11 causative of FHL4 abrogates syntaxin-11 binding to Munc18-2. Front. Immunol., 4, 2014, 515, 10.3389/fimmu.2013.00515.
177. Nakamura, L., Bertling, A., Brodde, M.F., Zur Stadt, U., Schulz, A.S., Ammann, S., et al. First characterization of platelet secretion defect in patients with familial hemophagocytic lymphohistiocytosis type 3 (FHL-3). Blood 125 (2015), 412–414, 10.1182/blood-2014-07-587568.
178. Harper, M.T., van den Bosch, M.T., Hers, I., Poole, A.W., Platelet dense granule secretion defects may obscure α-granule secretion mechanisms: evidence from Munc13-4-deficient platelets. Blood 125 (2015), 3034–3036, 10.1182/blood-2014-12-618439.
179. Zhang, K., Jordan, M.B., Marsh, R.A., Johnson, J.A., Kissell, D., Meller, J., et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 118 (2011), 5794–5798, 10.1182/blood-2011-07-370148.
180. Wang, Y., Wang, Z., Zhang, J., Wei, Q., Tang, R., Qi, J., et al. Genetic features of late onset primary hemophagocytic lymphohistiocytosis in adolescence or adulthood. PLoS ONE, 9, 2014, e107386, 10.1371/journal.pone.0107386.
181. House, I.G., Thia, K., Brennan, A.J., Tothill, R., Dobrovic, A., Yeh, W.Z., et al. Heterozygosity for the common perforin mutation, p.A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals. Immunol. Cell Biol. 93 (2015), 575–580, 10.1038/icb.2015.1.
182. Zhang, K., Chandrakasan, S., Chapman, H., Valencia, C.A., Husami, A., Kissell, D., et al. Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis. Blood 124 (2014), 1331–1334, 10.1182/blood-2014-05-573105.
183. Spessott, W.A., Sanmillan, M.L., McCormick, M.E., Patel, N., Villanueva, J., Zhang, K., et al. Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion. Blood 125 (2015), 1566–1577, 10.1182/blood-2014-11-610816.
184. Enders, A., Zieger, B., Schwarz, K., Yoshimi, A., Speckmann, C., Knoepfle, E.-M., et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky–Pudlak syndrome type II. Blood 108 (2006), 81–87, 10.1182/blood-2005-11-4413.
185. Gao, L., Zhu, L., Huang, L., Zhou, J., Synergistic defects of UNC13D and AP3B1 leading to adult hemophagocytic lymphohistiocytosis. Int. J. Hematol., 2015, 10.1007/s12185-015-1807-z.
186. Crozat, K., Hoebe, K., Ugolini, S., Hong, N.A., Janssen, E., Rutschmann, S., et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J. Exp. Med. 204 (2007), 853–863, 10.1084/jem.20062447.
187. Kögl, T., Müller, J., Jessen, B., Schmitt-Graeff, A., Janka, G., Ehl, S., et al. Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood 121 (2013), 604–613, 10.1182/blood-2012-07-441139.
188. Orange, J.S., Formation and function of the lytic NK-cell immunological synapse. Nat. Rev. Immunol. 8 (2008), 713–725, 10.1038/nri2381.
189. Sepulveda, F.E., Maschalidi, S., Vosshenrich, C.A.J., Garrigue, A., Kurowska, M., Ménasché, G., et al. A novel immunoregulatory role for NK-cell cytotoxicity in protection from HLH-like immunopathology in mice. Blood 125 (2015), 1427–1434, 10.1182/blood-2014-09-602946.
190. Waggoner, S.N., Cornberg, M., Selin, L.K., Welsh, R.M., Natural killer cells act as rheostats modulating antiviral T cells. Nature 481 (2012), 394–398, 10.1038/nature10624.
191. Lang, P.A., Lang, K.S., Xu, H.C., Grusdat, M., Parish, I.A., Recher, M., et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8 + T-cell immunity. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 1210–1215, 10.1073/pnas.1118834109.